Article Text

PDF
Original article
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy
  1. Ziad Hijazi1,
  2. Jonas Oldgren1,
  3. Ulrika Andersson2,
  4. Stuart J Connolly3,
  5. Michael D Ezekowitz4,
  6. Stefan H Hohnloser5,
  7. Paul A Reilly6,
  8. Agneta Siegbahn7,
  9. Salim Yusuf3,
  10. Lars Wallentin1
  1. 1Department of Cardiology, Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  2. 2Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
  3. 3Population Health Research Institute, Hamilton, Canada
  4. 4Thomas Jefferson Medical College and the Heart Center, Wynnewood, Pennsylvania, USA
  5. 5Department of Cardiology, J. W. Goethe University, Frankfurt, Germany
  6. 6Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA
  7. 7Department of Medical Sciences, Uppsala Clinical Research Center, Clinical Chemistry, Uppsala University, Uppsala, Sweden
  1. Correspondence to Dr Ziad Hijazi, Uppsala Clinical Research Center, Dag Hammarskjölds väg 14B, 1st floor, SE- 752 37 Uppsala, Sweden; Ziad.hijazi{at}ucr.uu.se

Abstract

Objectives To evaluate the prognostic importance of transient or persistent elevations of cardiac troponin-I (cTnI) and N-terminal-B-type natriuretic peptide (NT-proBNP) in atrial fibrillation (AF).

Methods Plasma samples were obtained at randomisation and after 3 months in 2514 patients with AF in the RE-LY trial; median follow-up was 2.0 years. Patients were grouped based on levels at the two time points according to detectable cTnI levels (≥0.01 µg/L) or NT-proBNP levels above median (≥778 ng/L). These groups were related to occurrence of stroke or cardiovascular events evaluated with Cox models adjusting for established risk factors.

Results The proportion of patients with detectable cTnI levels at both time points was 48.5%, at one time point 28.5% and at neither time point 21.0%. Patients with detectable cTnI at both time points had substantially higher rates of stroke compared with those with transient elevations and those with no elevation at either time point (p<0.005, effect of cTnI). Persistent elevation of either or both cardiac biomarkers at baseline and 3 months was associated with a higher risk for cardiovascular events and mortality (p<0.0001). Prognostic prediction improved most with the use of repeated measurements of both cardiac biomarkers simultaneously (p<0.05) and achieved C-statistic 0.644 for stroke compared with 0.611 for CHADS2-score.

Conclusions Persistent elevation of troponin and NT-proBNP indicates a worse prognosis than transient elevations or no elevations of either marker. Prognostication of stroke, death and thromboembolic events is improved by the use of repeated determinations of cardiac biomarkers.

Trial registration number: http://www.clinicaltrials.gov, NCT00262600

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles